Meijun Zhu, Jinhua Zhao, Lei Song*, Ming Xu, Juhua Ji


Department of Pediatrics, The First People's Hospital of Nantong (The second  affiliated hospital of Nantong university) PR China


Objective: To analyze the effects of 2063 locus gene mutation of 23S rRNA V region in MP pneumonia patients on macrolide drug resistance and DNA load. 

Methods: A total of 315 patients with respiratory infections admitted to our hospital from April 2015 to May 2018 were enrolled, and were tested for drug susceptibility, and were classified as the mutation group and non-mutation group according to whether or not the 2063 locus base mutations of the 23S rRNA v was detected; quantification and drug resistance genes of MP-DNA in alveolar lavage fluid of all patients with MP pneumonia were examined. 

Results: The isolated mycoplasma pneumoniae was positive by real-time fluorescent PCR detection of MP-DNA. Isolation of mycoplasma pneumoniae and drug susceptibility tests was conducted and showed that mycoplasma pneumoniae was more resistant to macrolide antibiotics. The MP-DNA load of the patients in the mutation group was significantly higher than that in the non-mutation group at all stages of the disease (P<0.05). Comparing the 2023 locus of MP23S rRNA V region in the case of macrolide drug resistance, it was found that more than 60% of macrolide-resistant patients detected G mutation at the 2063 locus. The average time of hospital stay, fever time, and fever relieving time of macrolides in the non-mutation group were significantly earlier than those in the mutation group, and the difference was statistically significant (P<0.01). 

Conclusion: The mutation of 2063 locus gene mutation in the 23S rRNA V region of MP pneumonia may have certain effects on macrolide resistance and DNA load, which may provide a theoretical basis for clinical treatment of MP.


MP pneumonia, 23S rRNA V region 2063 locus gene mutation, macrolides, drug resistance, DNA load.